Shanghai Serum Bio-Technology Co., Ltd. (SHA:688163)

China · Delayed Price · Currency is CNY

38.27

-0.43 (-1.11%)

At close: Sep 23, 2026

SHA:688163 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	199.6	196.21	194.92	190.14	174.22	208.69
Revenue Growth	0.97%	0.66%	2.51%	9.14%	-16.52%	12.46%
Gross Profit	153.17	151.2	149.11	140.3	140.72	172.36
Operating Income	54.93	52.25	46.15	33.22	50.45	82.03
Net Income	54.46	51.79	44.29	38.77	64.2	76.48
Earnings Per Share	0.51	0.48	0.41	0.36	0.63	0.94
EPS Growth	23.62%	17.07%	13.89%	-42.86%	-32.98%	20.51%

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
China	194.49
Overseas	1.72
Total	196.21

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	753.63	808.82	832.58	873.51	933.35	181.03
Total Debt	4.88	5.1	4.3	12.96	13.68	14.35
Net Cash (Debt)	748.75	803.73	828.28	860.55	919.66	166.68
Net Cash Growth	-1.33%	-2.96%	-3.75%	-6.43%	451.75%	40.97%
Net Cash Per Share	7.00	7.45	7.67	7.99	9.02	2.05

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	89.8	60.53	50.25	32.82	67.91	92.29
Capital Expenditures	-66.74	-59.61	-59.37	-28.67	-26.46	-27.61
Free Cash Flow	23.06	0.93	-9.12	4.15	41.46	64.68
Free Cash Flow Growth	-	-	-	-90.00%	-35.91%	-19.58%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	76.74%	77.06%	76.50%	73.79%	80.77%	82.59%
Operating Margin	27.52%	26.63%	23.68%	17.47%	28.96%	39.30%
Pretax Margin	33.27%	32.72%	25.94%	23.88%	42.50%	42.11%
Profit Margin	27.29%	26.39%	22.72%	20.39%	36.85%	36.65%
FCF Margin	11.55%	0.47%	-4.68%	2.18%	23.79%	30.99%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 23, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	0.380	0.380	0.320	0.200	0.750	0.900
Dividend Per Share Growth	18.75%	18.75%	60.00%	-73.33%	-16.67%	-
Dividend Yield	0.99%	1.76%	1.87%	1.05%	3.85%	-

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 23, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	75.15	45.49	42.91	55.79	35.55	-
P/FCF Ratio	179.57	2545.69	-	521.89	55.06	-
PS Ratio	20.75	12.01	9.75	11.38	13.10	-